Syndrome  >>  Tekturna (aliskiren)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT00409578 / 2006-001763-36: Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Completed
2
1101
US, Canada, Europe, RoW
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Novartis, The TIMI Study Group
Post Acute Coronary Syndrome, Myocardial Ischemia
04/09
04/09
NCT00417170: Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Completed
2
48
US
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Novartis Pharmaceuticals
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
07/10
07/10
ARIANA-CHF-RD, NCT00881439: Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment

Terminated
2
41
Europe
Aliskiren, Rasilez, SPP100, Placebo
University Medical Center Groningen
Heart Failure, Kidney Failure
07/12
12/12

Download Options